SCHEMBL20252564

SCHEMBL20252564

CN(Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)N(C(=O)OC(C)(C)C)c2cscn2)c(F)c1)C(C)(C)C

nearest known ligand 0.66

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 20/20 0.66
NR1I2 O75469 2/20 0.66
CYP1A2 P05177 2/20 0.66
CYP3A4 P08684 2/20 0.66
CYP2D6 P10635 2/20 0.66
CYP2C9 P11712 2/20 0.66
CYP2C19 P33261 2/20 0.66
SCN1B Q07699 2/20 0.66
SCN9A Q15858 2/20 0.66
SCN2A Q99250 2/20 0.66
KCNH2 Q12809 1/20 0.66
SCN1A P35498 19/20 0.58
SCN5A Q14524 19/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20238269 0.92 SCN8A (0.68) SCN8ANR1I2CYP1A2CYP3A4CYP2D6
SCHEMBL20252562 0.89 SCN8A (0.58) SCN8ANR1I2CYP1A2CYP3A4CYP2D6
SCHEMBL20238815 0.86 SCN8A (0.65) SCN8ANR1I2CYP1A2CYP3A4CYP2D6
SCHEMBL21783344 0.86 SCN8A (0.68) SCN8ANR1I2CYP1A2CYP3A4CYP2D6
SCHEMBL20256353 0.86 SCN1A (0.62) SCN8ASCN1ASCN5A
SCHEMBL30046056 0.86 SCN8A (0.68) SCN8ANR1I2CYP1A2CYP3A4CYP2D6
SCHEMBL20252639 0.86 SCN8A (0.62) SCN8ANR1I2CYP1A2CYP3A4CYP2D6
SCHEMBL21783351 0.84 SCN8A (0.68) SCN8ANR1I2CYP1A2CYP3A4CYP2D6
SCHEMBL30047151 0.84 SCN8A (0.68) SCN8ANR1I2CYP1A2CYP3A4CYP2D6
SCHEMBL21783517 0.84 SCN8A (0.69) SCN8ANR1I2CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3551626-B1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2023-10-25 EP disclosed
EP-3551626-B1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC (CA) 2023-10-25 EP disclosed
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-11-16 US disclosed
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2021-06-10 US disclosed
US-20180162868-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2018-06-14 US disclosed
US-20180162868-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2018-06-14 US disclosed
WO-2018106284-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2018-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents KCND2, SCN1A, CACNA1D SCN8A 20/4885NR1I2 1491/4885CYP1A2 831/4885
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN8A 11/4885NR1I2 1203/4885CYP1A2 926/4885
US-20180162868-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN8A 11/4885NR1I2 1203/4885CYP1A2 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.